Skip to Main Content

Paper Details

Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
Annals of the Rheumatic Diseases
15
2021
C-reactive protein, CAD, CRP, CVD, HF, MTX, RA, cardiovascular disease, coronary artery disease, heart failure, methotrexate, patients, rheumatoid arthritis, stroke
Author NameAffiliation
Katherine P LiaoVA Boston Healthcare System
  • 1 - 1

Datasets

Release 1.2